In addition, he says, it stimulates the production of nitric oxide, which assists in boosting blood flow to injured tissues
However, oral formulations represent the most significant route-specific innovation, with the potential to expand the market by addressing injection anxiety and enabling primary care prescribing without specialized training
Then on April 30, 2026, the FDA published a Federal Register notice proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list
FAERS is a publicly available post-marketing safety surveillance database that contains adverse event reports, medication error reports, and product quality complaints reported by health professionals, pharmaceutical manufacturers, lawyers, and individual patients (15, 16)